Chugai Pharmaceuticals Achieves Primary Objectives for Generalised Myasthenia Gravis Treatment

A subsidiary of Roche, Chugai Pharmaceuticals, has met its primary objective for a late-stage trial analyzing Enspryng for the treatment of generalised myasthenia gravis. 

Generalized myasthenia gravis is an autoimmune neuromuscular disorder characterized by weakness and fatigue of voluntary muscles. 

The late-stage study demonstrated statistically notable findings in the primary outcome; however, the outcomes did not meet the organisation’s anticipated results. 

The treatment was assessed by the candidates’ ability to perform everyday tasks such as speaking, swallowing, breathing, experiencing double vision, and drooping eyelids. These results were compared to those not treated with Enspryng. 

Chugai has expressed its intention to further explore the treatment of other neurological autoimmune conditions, including myelin oligodendrocyte glycoprotein-associated disorder and thyroid eye disease. 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.